<DOC>
	<DOCNO>NCT01491737</DOCNO>
	<brief_summary>This randomize , open-label , two-arm , multi-center , Phase II study evaluate efficacy safety pertuzumab combination trastuzumab plus aromatase inhibitor ( AI ) first-line participant HER2-positive hormone receptor-positive advanced breast cancer . Participants randomize one two treatment arm ; Arm A ( pertuzumab combination trastuzumab plus AI ) Arm B ( trastuzumab plus AI ) . Participants may also receive induction chemotherapy ( taxane , either docetaxel paclitaxel ) investigator 's discretion combination assign treatment arm . The anticipated time study treatment disease progression , unacceptable toxicity , withdrawal consent , death whichever occur first .</brief_summary>
	<brief_title>A Study Pertuzumab Combination With Trastuzumab Plus Aromatase Inhibitor Participants With Metastatic Human Epidermal Growth Factor Receptor 2 ( HER2 ) -Positive Hormone Receptor-Positive Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>Participants HER2positive hormone receptorpositive advance metastatic locally advanced breast cancer Postmenopausal status 1 year HER2positive assess local laboratory primary metastatic tumor Hormonereceptor positive define estrogen receptorpositive and/or progesterone receptorpositive At least one measurable lesion and/or nonmeasurable disease evaluable accord Response Evaluation Criteria In Solid Tumors Version 1.1 Previous systemic nonhormonal anticancer therapy metastatic locally advanced breast cancer set Previous treatment antiHER2 agent breast cancer , except trastuzumab and/or lapatinib neoadjuvant adjuvant set Disease progression receive adjuvant trastuzumab and/or lapatinib treatment History persistent Grade 2 high hematological toxicity accord National Cancer InstituteCommon Toxicity Criteria Version 4.0 Diseasefree interval completion adjuvant/neoadjuvant systemic nonhormonal treatment recurrence within 6 month Other malignancy within last 5 year , except carcinoma situ cervix basal cell carcinoma Clinical radiographic evidence central nervous system metastases significant cardiovascular disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>